Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Osteosarcoma: early-phase trial registry
27 of 47 indexed Osteosarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #307 of 28,707 conditions by registered trial count.
47 US clinical trials · 27 currently recruiting · #307 of 28,707 conditions by registered trial count
Osteosarcoma: 47 US clinical trials tracked, 27 recruiting.
Osteosarcoma is the subject of 47 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 35 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 4 of these trials.
Enrollment posture brief
Registry condition osteosarcoma
OPEN 27 | RECR 57% | LATE 1 | EARLY 35 | RANK #307 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Endometrial Cancer (57% recruiting · 188 trials)
Osteosarcoma lists 27 open slots (57% of 47 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Osteosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Osteosarcoma is recruiting above its size-band peers.
27 of 47 indexed trials (57.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Osteosarcoma trials is spread across many organizations.
Children's Oncology Group accounts for 4 of 47 trials (8.5%). 34 distinct sponsors appear on at least one study for this condition label.
-
Most Osteosarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 47 trials that report a genuine target (sentinel values excluded). 36 of those (76.6%) plan for fewer than 100 participants.
-
Osteosarcoma research is mostly interventional.
39 interventional and 8 observational studies make up this index (83% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
47 total, page 1 of 1
Clinical Orthopaedic Data Bank (Acute and Chronic)
University of Florida
NCT00411060
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Children's Oncology Group
NCT01790152
Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
Memorial Sloan Kettering Cancer Center
NCT03442465
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
NCT06465199
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
Ricoh USA
NCT06387485
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
NCT06541262
Pediatric PET/MR Image Registry
Stanford University
NCT03458520
AOH1996 for the Treatment of Refractory Solid Tumors
City of Hope Medical Center
NCT05227326
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
David S Shulman, MD
NCT06709495
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Children's Oncology Group
NCT05235165
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT04282044
Musculoskeletal Cancers Remote Monitoring and Care
Case Comprehensive Cancer Center
NCT07129226
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
MedPacto
NCT05588648
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
NCT07477457
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Medical College of Wisconsin
NCT04040205
Losartan + Sunitinib in Treatment of Osteosarcoma
University of Colorado, Denver
NCT03900793
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Crystal Mackall, MD
NCT06500819
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma
Jonsson Comprehensive Cancer Center
NCT06064682
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
NCT04897321
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Children's Hospital of Philadelphia
NCT06156410
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Baylor College of Medicine
NCT04995003
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT02508038
SPEARHEAD-3 Pediatric Study
Uswm CT
NCT05642455
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
UNC Lineberger Comprehensive Cancer Center
NCT03721068
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Emory University
NCT06492954
Upfront Surgical Resection for Osteosarcoma
Montefiore Medical Center
NCT06384404
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Ann & Robert H Lurie Children's Hospital of Chicago
NCT06235125
Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00580385
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
NCT02867592
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
NCT06521567
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT04483778
Olaparib With Ceralasertib in Recurrent Osteosarcoma
Dana-Farber Cancer Institute
NCT04417062
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Sarcoma Alliance for Research through Collaboration
NCT04803877
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT03618381
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Cellectar Biosciences
NCT03478462
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
Baylor College of Medicine
NCT01953900
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
H. Lee Moffitt Cancer Center and Research Institute
NCT03628209
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
Seattle Children's Hospital
NCT05312411
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
OHSU Knight Cancer Institute
NCT03960177
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
Ipsen
NCT06341712
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
Children's Oncology Group
NCT03206450
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
National Cancer Institute (NCI)
NCT00001209
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
St. Jude Children's Research Hospital
NCT00187109
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
Emory University
NCT01331135
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Timothy Cripe
NCT00931931
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Cancer Institute (NCI)
NCT02107963
Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma
Children's Oncology Group
NCT01807143
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Osteosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Osteosarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Osteosarcoma page
47 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Osteosarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Children's Oncology Group sponsors the most Osteosarcoma trials on record, review their full trial history before evaluating a specific study. See Children's Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Osteosarcoma condition card totals 47 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.